Deadline Alert: Tenax Therapeutics, Inc. Shareholders Have Until December 28, 2026 to Seek Lead Plaintiff Appointment in Securities Fraud Lawsuit, The Law Offices of Frank R. Cruz Notes

Lawsuit covers investors who acquired Tenax Therapeutics, Inc. securities from November 13, 2023 to August 7, 2026; complaint alleges the company made misleading statements to investors

LOS ANGELES--(BUSINESS WIRE)--The deadline for Tenax Therapeutics, Inc. ("Tenax" or the "Company") (NASDAQ: TENX) investors to seek appointment as lead plaintiff in a securities class action lawsuit is December 28, 2026. The lawsuit was filed on behalf of investors who purchased or otherwise acquired Tenax Therapeutics, Inc. securities from November 13, 2023 to August 7, 2026, inclusive. The Law Offices of Frank R. Cruz today reminded investors of the deadline in the case, Katz v. Tenax Therapeutics, Inc. et al., filed on October 26, 2026 in the U.S. District Court North Carolina Middle District (Case No. 1:26-cv-01264).

If you lost money on Tenax Therapeutics, Inc. securities, submit your Tenax Therapeutics, Inc. loss information before the December 28, 2026 deadline to learn about your potential claims under the federal securities laws.

Tenax Therapeutics, Inc. deadline and case dates

• Lead plaintiff motion deadline: December 28, 2026
• Class period: November 13, 2023 to August 7, 2026, inclusive
• Filed: October 26, 2026
• Court: U.S. District Court North Carolina Middle District

What happened?

On August 10, 2026, Tenax issued a press release reporting topline results from its Phase 3 LEVEL clinical trial. The press release stated that TNX-103 "did not meet its primary endpoint of improvement in the 6-minute walk distance versus placebo, or the key secondary endpoint of improvement in Kansas City Cardiomyopathy Questionnaire total symptom score."

On this news, Tenax's stock fell $12.06 per share, or 89.77%, to close at $1.38 per share on August 10, 2026, thereby injuring investors.

What is the Tenax Therapeutics, Inc. lawsuit about?

The Tenax Therapeutics, Inc. class action alleges that, throughout the class period, defendants made materially false and/or misleading statements and failed to disclose material adverse facts about Tenax Therapeutics, Inc.'s business, operations, and prospects. Specifically, the complaint alleges defendants failed to disclose to investors that: (1) TNX-103 was less effective than Defendants had led investors to believe; (2) accordingly, TNX-103's overall clinical, regulatory, and commercial prospects were overstated; and (3) as a result, defendants' positive statements about Tenax Therapeutics, Inc.'s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

Investors who purchased or otherwise acquired Tenax Therapeutics, Inc. securities during the class period may ask the Court, no later than December 28, 2026, to appoint them lead plaintiff in this putative class action lawsuit.

"According to the complaint filed against Tenax Therapeutics, Inc., the Company, among other things, did not disclose that TNX-103 was less effective than Defendants had led investors to believe. With the December 28, 2026 deadline drawing near, investors who want a voice in how this case is led should reach out now," said Frank R. Cruz of The Law Offices of Frank R. Cruz.

What should Tenax Therapeutics, Inc. investors do now?

The Law Offices of Frank R. Cruz can help Tenax Therapeutics, Inc. investors evaluate potential claims to recover their losses. Investors who want to serve as lead plaintiff must file a motion with the Court by December 28, 2026. For more information, visit the Tenax Therapeutics, Inc. case page, email [e-mail], or call 310-914-5007.

If you inquire by email, please include your mailing address, telephone number, and number of shares purchased.

Tenax Therapeutics, Inc. investors need not take any action at this time to be class members. Investors may retain counsel of their choice or take no action and remain absent class members. No class has been certified yet in the Tenax Therapeutics, Inc. case.

Questions and answers about the Tenax Therapeutics, Inc. deadline

Who is eligible? Investors who bought Tenax Therapeutics, Inc. securities between November 13, 2023 and August 7, 2026 and lost money may be class members in the Tenax Therapeutics, Inc. securities lawsuit.

When are lead plaintiff motions due in the Tenax Therapeutics, Inc. case? Lead plaintiff motions in the Tenax Therapeutics, Inc. class action are due in the U.S. District Court North Carolina Middle District by December 28, 2026.

What happens after the Tenax Therapeutics, Inc. deadline passes? After December 28, 2026, investors generally can no longer seek lead plaintiff appointment, but Tenax Therapeutics, Inc. investors may still remain class members.

How are attorneys' fees handled? The Law Offices of Frank R. Cruz works on contingency, so Tenax Therapeutics, Inc. investors pay no attorneys' fees up front. Any attorneys' fees and litigation expenses come only from a recovery, if there is one, and require court approval.

About The Law Offices of Frank R. Cruz

The Law Offices of Frank R. Cruz investigates and prosecutes securities fraud and corporate malfeasance class actions. With nearly 20 years of litigation experience, the firm focuses on complex securities class actions and gives each client personal, one-on-one attention throughout the legal process.

Prior results do not guarantee a similar outcome.

Related links

• Tenax Therapeutics, Inc. case page, The Law Offices of Frank R. Cruz
• Complaint: Katz v. Tenax Therapeutics, Inc. et al., U.S. District Court North Carolina Middle District
• Tenax Press Release
• Tenax Therapeutics, Inc. SEC filings index, EDGAR
• The Law Offices of Frank R. Cruz

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.